Literature DB >> 7205298

Reversal by phenytoin of carbamazepine-induced water intoxication: a pharmacokinetic interaction.

E Perucca, A Richens.   

Abstract

The hypothesis that phenytoin may antagonise the antidiuretic effect of carbamazepine has been examined by comparing the free water clearance response to a standard water load in 36 patients stabilised on different drug regimes. The diuretic response to the water load was significantly greater in patients receiving chronic treatment with carbamazepine and phenytoin in combination than in matched control subjects receiving carbamazepine as a single drug. Acute administration of phenytoin (1,100 mg), however, had no significant influence on carbamazepine-induced antidiuresis. Evidence is presented that reversal of the antidiuretic effect of carbamazepine by chronic phenytoin administration is secondary to a marked reduction of the serum carbamazepine concentration during combined therapy. These results suggest that the risk of developing water intoxication is greater in patients receiving carbamazepine alone than in those receiving phenytoin in combination. Since the antidiuretic effect is correlated with the serum carbamazepine concentration rather than with the prescribed daily dose, monitoring the serum level of the drug is likely to provide the best rational approach to the prevention of excessive water retention.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7205298      PMCID: PMC490597          DOI: 10.1136/jnnp.43.6.540

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  Raised plasma arginine vasopressin concentration in carbamazepine-induced water intoxication.

Authors:  N J Smith; M L Espir; P H Baylis
Journal:  Br Med J       Date:  1977-09-24

2.  Water intoxication associated with carbamazepine treatment.

Authors:  M G Ashton; S G Ball; T H Thomas; M R Lee
Journal:  Br Med J       Date:  1977-04-30

3.  Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy.

Authors:  J Christiansen; M Dam
Journal:  Acta Neurol Scand       Date:  1973       Impact factor: 3.209

4.  Inhibition of antidiuretic hormone secretion by diphenylhydantoin.

Authors:  M P Fichman; C R Kleeman; J E Bethune
Journal:  Arch Neurol       Date:  1970-01

5.  The efficacy of carbamazepine combinations in epilepsy.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

6.  Water intoxication due to carbamazepine.

Authors:  W P Stephens; M L Espir; R B Tattersall; N P Quinn; S R Gladwell; A W Galbraith; E H Reynolds
Journal:  Br Med J       Date:  1977-03-19

7.  Hyponatraemia during carbamazepine treatment.

Authors:  D A Henry; D H Lawson; P Reavey; S Renfrew
Journal:  Br Med J       Date:  1977-01-08

8.  Kinetics of carbamazepine and its 10,11-epoxide metabolite in children.

Authors:  A Rane; B Höjer; J T Wilson
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

9.  Plasma level and effect of carbamazepine in grand mal and psychomotor epilepsy.

Authors:  M Dam; A Jensen; J Christiansen
Journal:  Acta Neurol Scand Suppl       Date:  1975

10.  Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva.

Authors:  H G Westenberg; E van der Kleijn; T T Oei; R A de Zeeuw
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

View more
  11 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 3.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

4.  Plasma arginine vasopressin concentrations in epileptics under monotherapy.

Authors:  K H Krause; W Rascher; P Berlit
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

Review 5.  Drug interactions with phenytoin.

Authors:  E Perucca; A Richens
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

6.  Lack of efficacy of phenytoin in the syndrome of inappropriate anti-diuretic hormone secretion of neurological origin.

Authors:  G Decaux; S Przedborski; A Soupart
Journal:  Postgrad Med J       Date:  1989-07       Impact factor: 2.401

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 9.  Drug interactions with St John's wort : mechanisms and clinical implications.

Authors:  Marcus Mannel
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin.

Authors:  M L Lai; T S Lin; J D Huang
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.